J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Atrazine and nitrate in public drinking water supplies and non-hodgkin lymphoma in nebraska, USA.
Martha Rhoades,Jane L. Meza,Cheryl L. Beseler,Patrick J. Shea,Andy Kahle,Julie M. Vose,Kent M. Eskridge,Roy F. Spalding +7 more
TL;DR: A secondary analysis of 1999-2002 Nebraska case-control data was conducted to assess the risk of non-Hodgkin lymphoma (NHL) associated with exposure to nitrate- and atrazine-contaminated drinking water, and found no association between NHL risk and exposure to drinking water containing atrazin or nitrate alone.
Journal ArticleDOI
Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Michael D. Jain,Miriam T. Jacobs,Loretta J. Nastoupil,Jay Y. Spiegel,Gao Feng,Yi Lin,Matthew A. Lunning,Saurabh Dahiya,Lazaros J. Lekakis,Patrick M. Reagan,Olalekan O. Oluwole,Joseph P. McGuirk,Abhinav Deol,Andre Goy,Brian T. Hill,Javier Munoz,Julio C. Chavez,Aaron P. Rapoport,Julie M. Vose,David B. Miklos,Sattva S. Neelapu,N. Nora Bennani,Charalambos Andreadis,Alison R. Sehgal,Armin Ghobadi,Frederick L. Locke +25 more
TL;DR: Patients receiving bridging therapy for axi-cel in a large multicenter cohort of 276 patients receiving CAR T infusion with a median follow up of 9 months are evaluated.
Journal ArticleDOI
Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS)
Jonathan W. Friedberg,J. Huang,Hildy Dillon,Charles M. Farber,S. Feliciano,John D. Hainsworth,Brian K. Link,R. Steis,Julie M. Vose,Andrew D. Zelenetz +9 more
TL;DR: Diverse regimens are used for initial management of FL in the United States and significant differences among regions and between center types suggest physician preference may drive initial therapy.
Journal ArticleDOI
Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma
Nilesh W. Gaikwad,Li Yang,Dennis D. Weisenburger,Julie M. Vose,Cheryl L. Beseler,Eleanor G. Rogan,Ercole L. Cavalieri +6 more
TL;DR: Estrogen metabolites, conjugates and depurinating DNA adducts were identified and quantified in spot urine samples from 15 men with NHL and 30 healthy control men by using ultraperformance liquid chromatography/tandem mass spectrometry.
Journal ArticleDOI
Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease.
Joseph H. Sisson,Austin B. Thompson,James R. Anderson,Richard A. Robbins,John R. Spurzem,Paul R. Spence,Elizabeth C. Reed,James O. Armitage,Julie M. Vose,Mark A. Arneson,William P. Vaughan,Stephen I. Rennard +11 more
TL;DR: It is demonstrated that bronchial inflammation is present with or without intraluminal inflammatory cells in the majority of patients with Hodgkin disease before BMT and the subgroup of these patients with increasedBronchial inflammatory cells are at greatly increased risk for development of DAH and death.